Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bio-Path, a biotechnology company with drug development operations in Houston, Texas, has dosed first patient with Liposomal Grb-2 (L-Grb-2 or BP-100-1.01), its cancer drug candidate, in a Phase I study evaluating patients with acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL) or myelodysplastic syndrome (MDS).
Subscribe to our email newsletter
Bio-Path stated that the Phase I clinical trial is a dose-escalating study to determine the safety and tolerance of escalating doses of L-Grb-2. The pharmacokinetics of L-Grb-2 in patients will be studied, making it possible to investigate whether the delivery technology performs as expected based on pre-clinical studies in animals. The trial is expected to evaluate five doses of L-Grb-2.
Peter Nielsen, president and CEO of Bio-Path, said: “Liposomal Grb-2 is the first cancer drug candidate in Bio-Path’s lipid vehicle delivery platform to begin clinical trials.
“A second important outcome for the Phase I clinical trial is the ability to assess the performance of the company’s delivery technology platform in human patients.
“Being platform technology, a successful demonstration of the delivery technology in this study will allow the company to immediately begin expanding Bio-Path’s drug candidates by simply applying the delivery technology template to multiple new drug product targets.”